Company
Headquarters: Tokyo, Japan
Employees: 7,664
CEO: Dr. Osamu Okuda
¥13.781 Trillion
JPY as of Jan. 1, 2026
US$87.94 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| AstraZeneca | $284.38 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | ¥1.214 T |
| EBITDA | ¥542.00 B |
| Gross Profit TTM | ¥843.28 B |
| Profit Margin | 32.72% |
| Operating Margin | 46.97% |
| Quarterly Revenue Growth | 5.50% |
Chugai Pharmaceutical Co. Ltd has the following listings and related stock indices.
Stock: JPX: 4519
Stock: FSX: CUP
Stock: OTC: CHGCF
Stock: OTC: CHGCY